ID: ALA2385592

Max Phase: Preclinical

Molecular Formula: C24H21N5S

Molecular Weight: 411.53

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  c1ccc2c(-c3cnn4cc(-c5ccc(N6CCNCC6)cc5)cnc34)csc2c1

Standard InChI:  InChI=1S/C24H21N5S/c1-2-4-23-20(3-1)22(16-30-23)21-14-27-29-15-18(13-26-24(21)29)17-5-7-19(8-6-17)28-11-9-25-10-12-28/h1-8,13-16,25H,9-12H2

Standard InChI Key:  WWJXFRWWRLRVCD-UHFFFAOYSA-N

Associated Targets(non-human)

Bone morphogenetic protein 4 32 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 411.53Molecular Weight (Monoisotopic): 411.1518AlogP: 4.69#Rotatable Bonds: 3
Polar Surface Area: 45.46Molecular Species: BASEHBA: 6HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 8.87CX LogP: 4.40CX LogD: 2.92
Aromatic Rings: 5Heavy Atoms: 30QED Weighted: 0.47Np Likeness Score: -1.63

References

1. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR..  (2013)  Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.,  23  (11): [PMID:23639540] [10.1016/j.bmcl.2013.03.113]

Source